Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have improved outcomes for several malignancies, but cancer patients face an increased risk of cardiovascular disease due to shared risk factors, similar biological mechanisms, and cardiotoxic side effects of therapy. Effective risk stratification strategies are urgently needed.

Objectives

This study explored the association between the biomarkers with the risks of acute cardiovascular hospitalizations and death in cancer patients receiving ICI therapy.

Methods

We used electronic health records of patients treated with ICI who had available baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at Vienna General Hospital between January 2017 and July 2022. The primary outcome of interest was the composite o

SUBMITTER: Mann C 

PROVIDER: S-EPMC12335986 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature